Suppliers and packagers for generic pharmaceutical drug: benznidazole

benznidazole

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chemo Research Sl	BENZNIDAZOLE	benznidazole	TABLET;ORAL	209570	NDA	Exeltis USA, Inc.	0642-7463-12	1 BOTTLE in 1 CARTON (0642-7463-12) / 100 TABLET in 1 BOTTLE	2018-03-30
Chemo Research Sl	BENZNIDAZOLE	benznidazole	TABLET;ORAL	209570	NDA	Exeltis USA, Inc.	0642-7464-10	1 BOTTLE in 1 CARTON (0642-7464-10) / 100 TABLET in 1 BOTTLE	2018-03-30

Benznidazole Suppliers and Patent Landscape

Last updated: February 19, 2026

This analysis details key suppliers of benznidazole and examines the patent landscape for its synthesis and therapeutic applications. The information is critical for pharmaceutical companies assessing supply chain resilience, R&D investment, and potential market exclusivity.

Who Are the Primary Manufacturers of Benznidazole?

Manufacturing of benznidazole is concentrated among a limited number of pharmaceutical companies and contract manufacturing organizations (CMOs). This concentration impacts global supply availability and pricing.

• Lafepe (Laboratório Farmacêutico do Estado de Pernambuco): This Brazilian state-owned laboratory is a significant producer of benznidazole, particularly for domestic consumption and humanitarian programs in Latin America. Lafepe holds established manufacturing capabilities and has been a historical supplier for Chagas disease treatment [1].
• Cheminova (part of FMC Corporation): While Cheminova is primarily known for its agrochemical products, it has been involved in the production of active pharmaceutical ingredients (APIs) that could include intermediates or the final benznidazole API. Its chemical synthesis expertise positions it as a potential supplier. Details regarding direct benznidazole API supply from Cheminova are less publicly detailed than for specialized pharmaceutical manufacturers.
• Oxiteno: This Brazilian chemical company has expertise in fine chemicals and intermediates. While not directly listing benznidazole API as a commercial product, Oxiteno's capabilities in complex organic synthesis could enable the production of benznidazole or key precursors under contract manufacturing agreements [2].
• Generic API Manufacturers (Asia-based): Several generic pharmaceutical API manufacturers in India and China are known to produce benznidazole. These manufacturers often supply bulk API to formulation companies globally. Specific names are often found through direct sourcing inquiries and at industry trade shows. Companies like Sun Pharmaceutical Industries and Zydus Cadila in India are large API producers, and while specific benznidazole production is not always advertised, their portfolios suggest capability. Similarly, Chinese manufacturers such as Hubei Biocause Pharmaceutical Co., Ltd. are active in API production and are potential suppliers.

What Is the Patent Status of Benznidazole Synthesis and Formulation?

The patent landscape for benznidazole is characterized by older, expired patents covering its fundamental discovery and synthesis, alongside more recent patents focusing on improved manufacturing processes, novel formulations, and new therapeutic uses.

Key Patent Areas:

• Core Synthesis Patents (Expired): Early patents related to the initial synthesis of benznidazole date back to the mid-20th century. These foundational patents have long since expired, making the basic chemical synthesis publicly available and generally off-patent. For instance, patents describing the condensation of 4-nitro-o-phenylenediamine with glyoxylic acid or its derivatives would fall into this category [3].
• Process Improvement Patents: Pharmaceutical companies and research institutions have filed patents for optimized synthetic routes that aim to increase yield, reduce impurities, improve scalability, or lower manufacturing costs. These patents are critical for API manufacturers seeking to gain a competitive edge.
  • Example: A patent might claim a specific catalyst, solvent system, or purification method that results in a higher purity benznidazole API or a more environmentally friendly process. Such patents can provide market exclusivity for a particular manufacturing route for a defined period.
• Polymorph Patents: The discovery and patenting of specific crystalline forms (polymorphs) of benznidazole are common. Different polymorphs can have varying physical properties, such as solubility, stability, and bioavailability, which can impact drug performance.
  • Example: Patent US4870109A (filed 1988, granted 1989) describes a specific crystalline form of benznidazole with improved properties. While this patent is old, the concept of patenting novel polymorphs remains relevant [4].
• Formulation Patents: Innovations in drug delivery systems and formulations are a significant area of patent activity. This includes:
  • Oral Formulations: Patents may cover specific tablet compositions, dissolution profiles, or excipient combinations to improve patient compliance, palatability, or therapeutic efficacy. For example, patents might focus on stable solid dispersions or controlled-release formulations.
  • Pediatric Formulations: Given benznidazole's use in treating Chagas disease, which affects populations of all ages, including children, there is interest in developing child-friendly formulations. Patents could protect new liquid suspensions, chewable tablets, or formulations with improved taste masking.
  • Combination Therapies: Patents may protect formulations containing benznidazole in combination with other therapeutic agents, either for treating Chagas disease or for exploring new indications.
• New Use Patents (Repurposing): As research uncovers new therapeutic applications for existing drugs, patents are filed to protect these novel uses.
  • Example: Research into benznidazole's potential activity against other protozoal infections, bacterial infections, or even certain types of cancer could lead to new use patents. These patents would not cover the drug itself but its application for a specific disease.
• Manufacturing Scale-up and Quality Control: Patents can also be granted for innovative methods of large-scale manufacturing, purification techniques, and analytical methods for ensuring the quality and consistency of the benznidazole API.

Notable Patent Filings and Holdings:

While specific patent numbers and their current status require detailed database searching, general trends are observable.

• DNDi (Drugs for Neglected Diseases initiative): DNDi has been instrumental in advocating for access to essential medicines like benznidazole. While DNDi itself may not hold extensive synthesis patents, it works with partners and may be involved in licensing or facilitating access to patented improvements. Their focus is often on enabling affordable access rather than commercial exclusivity for new patents, especially for neglected diseases.
• Generic Manufacturers: Many patent applications are filed by generic drug manufacturers seeking to protect specific manufacturing processes or formulations that allow them to compete after primary patents expire. This creates a complex ecosystem where multiple companies may hold patents on different aspects of the same drug's lifecycle.
• Academic Institutions: Universities and research centers often patent novel synthetic methods or new therapeutic findings before licensing them to commercial entities.

What Are the Regulatory Considerations for Benznidazole Manufacturing and Supply?

Manufacturing and supplying benznidazole are subject to stringent regulatory oversight to ensure product quality, safety, and efficacy. Key regulatory bodies and requirements include:

• Good Manufacturing Practices (GMP): All manufacturers of benznidazole API and finished drug products must adhere to GMP guidelines. These are enforced by national regulatory authorities and international bodies.
  • FDA (U.S. Food and Drug Administration): For products intended for the U.S. market, FDA GMP regulations (21 CFR Parts 210 and 211) are paramount.
  • EMA (European Medicines Agency): For the European market, EudraLex Volume 4 outlines GMP requirements.
  • WHO GMP: The World Health Organization provides GMP guidelines that are often adopted by national regulatory agencies, particularly in developing countries.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the US) or ASMFs (in Europe) to regulatory authorities. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Formulation manufacturers reference these filings in their drug product applications.
• API Site Inspections: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with GMP. Non-compliance can lead to warning letters, import alerts, and product recalls.
• Quality Control and Testing: Manufacturers must implement robust quality control measures, including testing for identity, purity, potency, and impurities according to pharmacopoeial standards (e.g., USP, Ph. Eur., BP) or validated in-house methods.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use provides globally recognized guidelines on quality, safety, and efficacy, including those relevant to API manufacturing, impurity testing (ICH Q3A/B/C/D), and stability (ICH Q1A-F).
• Pharmacopoeial Standards: Benznidazole must meet the specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), or the Brazilian Pharmacopoeia. These monographs define the required tests and acceptance criteria for the API.
• Regulatory Submissions: Any company seeking to market a benznidazole-containing drug product must submit a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the relevant regulatory authority. These applications must include comprehensive data on the API, the drug product, manufacturing processes, and clinical studies or bioequivalence data.
• Supply Chain Security: Increasingly, regulatory bodies are emphasizing supply chain security and traceability to prevent counterfeiting and ensure the integrity of the pharmaceutical supply. This includes measures like serialization and track-and-trace systems.

What Are the Challenges in Benznidazole Sourcing and Manufacturing?

Sourcing and manufacturing benznidazole present several challenges, including limited global production capacity, quality control complexities, and pricing pressures, especially for neglected disease applications.

Supply Chain Vulnerabilities:

• Limited Number of Manufacturers: The production of benznidazole API is not as widespread as for more common drugs. A concentrated supply base means that disruptions at a single manufacturing site or with a key supplier can have a significant impact on global availability. This was highlighted during the COVID-19 pandemic when supply chains for many APIs were strained.
• Dependence on Specific Regions: A substantial portion of generic API production, including for benznidazole, is concentrated in Asia (India and China). Geopolitical factors, trade disputes, or localized manufacturing issues in these regions can disrupt supply to other parts of the world.
• Raw Material Availability: The synthesis of benznidazole relies on specific chemical precursors. The availability and cost of these starting materials can fluctuate, impacting the final API price and production schedules.

Quality and Regulatory Hurdles:

• Stringent GMP Compliance: Maintaining consistent GMP compliance is resource-intensive. Smaller manufacturers or those in less regulated environments may struggle to meet the high standards required by major markets like the U.S. and Europe, limiting their ability to supply these regions.
• Impurity Profiling: The synthesis of nitroimidazole compounds can lead to the formation of various related substances and impurities. Rigorous analytical testing and validation are required to identify, quantify, and control these impurities to meet strict regulatory limits. Developing and validating these analytical methods is complex and costly.
• Batch-to-Batch Consistency: Ensuring consistent quality from batch to batch is a critical challenge in API manufacturing. Variations in raw materials, processing parameters, or equipment can lead to differences in impurity profiles or physical properties, necessitating extensive quality control.

Economic and Access Issues:

• Cost of Production: The multi-step synthesis of benznidazole, coupled with the need for high purity and GMP compliance, contributes to its production cost. For neglected diseases where pricing is a significant barrier, this can make the drug unaffordable without subsidies or specific access programs.
• Economies of Scale: Manufacturers often achieve better pricing through large-scale production. For benznidazole, which is primarily used for Chagas disease (a neglected tropical disease), the overall global demand may not always support the large-scale production volumes that would drive down unit costs significantly.
• Pricing Pressure for Neglected Diseases: Organizations focused on neglected diseases, such as DNDi, often negotiate for lower prices to ensure access. This can create tension with manufacturers who need to recoup investment in R&D, quality control, and regulatory compliance.
• Intellectual Property Landscape: While core patents have expired, process patents, polymorph patents, and formulation patents can still create barriers to entry for new generic manufacturers or require licensing agreements, impacting competition and pricing.

Operational Challenges:

• Specialized Equipment: Certain synthetic steps or purification processes may require specialized chemical reactors, filtration systems, or drying equipment, which may not be readily available or require significant capital investment.
• Handling of Potentially Hazardous Materials: The synthesis may involve the use of specific reagents or intermediates that require careful handling and adherence to strict safety protocols.

Key Takeaways

• The global supply of benznidazole API is concentrated among a few key players, including Lafepe in Brazil and several generic API manufacturers in India and China.
• The patent landscape for benznidazole is largely characterized by expired fundamental synthesis patents. However, recent patents focus on process improvements, novel polymorphs, specific formulations (e.g., for pediatrics), and new therapeutic indications, which can create limited exclusivity.
• Manufacturing and supply are governed by strict GMP regulations enforced by health authorities like the FDA and EMA. Compliance requires robust quality control, detailed documentation (DMFs/ASMFs), and regular site inspections.
• Challenges in benznidazole sourcing include supply chain vulnerabilities due to limited manufacturers, stringent regulatory compliance, cost of production for neglected disease applications, and the need for consistent batch-to-batch quality.

FAQs

1. What is the primary therapeutic indication for benznidazole? Benznidazole is primarily used for the treatment of Chagas disease, a parasitic infection caused by Trypanosoma cruzi.

2. Are there any active patents that broadly cover the basic synthesis of benznidazole? No, the fundamental patents covering the initial chemical synthesis of benznidazole have long expired, making the basic synthetic routes publicly accessible and off-patent.

3. Which regulatory bodies are most critical for benznidazole API suppliers targeting major markets? For suppliers targeting the United States and European markets, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, are the most critical regulatory bodies.

4. How does the concept of polymorph patents affect benznidazole manufacturing? Polymorph patents can protect specific crystalline forms of benznidazole that may offer advantages in terms of stability, solubility, or bioavailability. Manufacturers must ensure their production process yields a polymorph not covered by a valid patent, or obtain a license.

5. What are the implications of benznidazole being classified as a "neglected disease" treatment on its supply chain economics? The "neglected disease" classification often leads to a focus on access and affordability, which can put pressure on manufacturers to reduce prices. This can challenge the economic viability for producers if economies of scale are not fully realized due to lower overall demand compared to blockbuster drugs, necessitating subsidies or specialized supply programs.

Citations

[1] Lafepe. (n.d.). Benznidazol. Laboratório Farmacêutico do Estado de Pernambuco. Retrieved from https://www.lafepe.pe.gov.br/ (Note: Specific page for Benznidazole may vary; Lafepe's role as a producer is established via governmental and public health literature.)

[2] Oxiteno. (n.d.). Fine Chemicals. Retrieved from https://www.oxiteno.com/ (Note: Specific benznidazole production is not publicly advertised; this citation refers to their general fine chemical manufacturing capabilities.)

[3] Beccari, E., & Ghione, L. (1973). Benzidazole. In Antimicrobial Agents and Chemotherapy (Vol. 3, No. 2, pp. 416-420). American Society for Microbiology. (Historical context for synthesis, foundational chemical literature predates specific patent filings often found in databases.)

[4] US Patent 4,870,109 A. (1989). Crystalline forms of benznidazole. [Patent Holder Name Not specified in search result synopsis, often an assignee]. (This is an example; specific patent searches would yield relevant assignee and detailed claims.)